BridgeBio have demonstrably advanced its development of a new therapy for cardiac amyloidosis, employing the compound. Initial trial data indicates significant benefits for patients suffering with the serious condition. https://attruby352612.smblogsites.com/42213963/bridgebio-progresses-attr-cm-treatment-with-the-drug